Amneal Pharmaceuticals (STU:2DT) Long-Term Debt : €2,226 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Long-Term Debt?

Amneal Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2024 was €2,226 Mil.

Amneal Pharmaceuticals's quarterly Long-Term Debt declined from Sep. 2023 (€2,420 Mil) to Dec. 2023 (€2,226 Mil) but then increased from Dec. 2023 (€2,226 Mil) to Mar. 2024 (€2,226 Mil).

Amneal Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (€2,406 Mil) to Dec. 2022 (€2,484 Mil) but then declined from Dec. 2022 (€2,484 Mil) to Dec. 2023 (€2,226 Mil).

Amneal Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Amneal Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Long-Term Debt Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

2,348.14

2,278.34

2,405.51

2,484.31

2,225.97

Amneal Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															2,430.13	2,390.33	2,420.10	2,225.97	2,226.03

Amneal Pharmaceuticals (STU:2DT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Amneal Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Amneal Pharmaceuticals (STU:2DT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (STU:2DT) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

AMRX:USA 2DT:Germany

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website

https://www.amneal.com

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Amneal Pharmaceuticals (STU:2DT) Headlines

No Headlines